Another "node your homework"....
In 1817, James Parkinson, a British physician, wrote a monograph, â€śAn Essay on the Shaking Palsyâ€ť. In it, he described a disease he termed â€śshaking palsyâ€ť (paralysis agitans). He noted â€śinvoluntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forwards, and to pass from a walking to a running pace: the senses and the intellect being uninjured.â€ť This disease, now known as Parkinsonâ€™s disease, is the subject of this writeup.
Parkinsonâ€™s disease is a progressively degenerative neurological disease. Its symptoms result from the degenerative loss of dopamine-producing neurons in two nuclei within the brain; one within the globus pallidum, and the other within the thalamus.
There are several different etiologies for Parkinsonâ€™s disease, including medications such as neuroleptics, antiemetics and some antihypertensives, toxins such as carbon monoxide, cyanide, manganese, herbicides, carbon disulfide, methanol and lacquer thinner, and the recreational drug Ecstasy. Other etiologies include acute brain infarction, structural brain lesions, and brain trauma (a subset of parkinsonism, dementia pugilistica, is seen in boxers). Some of Parkinsonâ€™s more famous victims in recent history include Muhammad Ali, Michael J. Fox, and Janet Reno.
Parkinsonâ€™s disease occurs worldwide. It affects approximately one million people in the United States. 50,000 new cases are diagnosed each year. There is an upward trend, due to the aging of the population as well as increased sensitivity of detection. The typical age of onset is between 55 and 60 years. However, five percent of all cases occur in persons under the age of 40. The male to female ratio is three to two.
A history of anxiety or depression doubles the risk of developing Parkinsonâ€™s disease. It is unknown whether anxiety and depression are early nonmotor manifestations of the disease, whether they in themselves increase the risk, or whether they simply tend to occur together. On the other hand, caffeine and nicotine intake has been shown to decrease the risk of developing Parkinsonâ€™s disease. It has been hypothesized that this may be due to a physical or psychological intolerance to caffeine or nicotine among people with a propensity for developing Parkinsonâ€™s disease, or that caffeine may increase central dopaminergic tone.
There is some evidence indicating a possible hereditary factor. Parkinsonâ€™s disease can be traced through several large family groups in Italy and Iceland; however, the Department of Veteransâ€™ Affairs Twin Study failed to show this link in disease that occurred at the typical age. There was a genetic factor in disease which occurred before age 40.
Symptoms of Parkinsonâ€™s disease usually begin very gradually, and may initially be taken for normal changes of aging. The initial symptom is usually an unilateral hand tremor which is most pronounced at rest. It intensifies with movement of the unaffected hand; however, it decreases and may disappear with use of the affected hand. Its intensity fluctuates, and increases with stress. The patient may also have a tremor in the lower jaw, tongue, and legs. Handwriting changes, such as decreased size and legibility of writing, slowing of movements, difficulty rising from a sitting position, and gait changes such as shuffling or foot dragging also occur. These symptoms initially manifest asymmetrically, and progress to the opposite side within two to three years of their appearance. Reduced volume and clarity of speech, as well as an absence of facial expression, are also evident. Rigidity of the limbs affected by the tremor leads to the characteristic â€ścogwheelingâ€ť movements, and can be assessed by performing range-of-motion testing. An increased muscle tone and lack of relaxation will be noted. Postural instability is a late sign of Parkinsonâ€™s disease.
In addition to the motor symptoms discussed above, there is a wide range of nonmotor symptoms as well.
Cognitive decline manifests as visual disturbance, memory deficit, or frank dementia. Depression is almost universal among Parkinsonâ€™s patients. Sleep disturbances such as frequent nighttime waking, excessive daytime drowsiness, and â€śrestless legâ€ť syndrome are common. Additionally, REM sleep behavior disorder, a condition in which physical activity occurs during REM sleep, may cause injur to either the patient or their bed partner.
Constipation, urinary problems, orthostatic hypotension and disturbances of diaphoresis, as well as limb paresthesias, sexual dysfunction and an impaired sense of smell are associated symptoms as well. Late in the course of the disease, dysphagia and dyspnea occur.
There are several other disorders which can be confused with Parkinsonâ€™s disease:
- Essential tremor is a tremor which is usually absent at rest. It worsens with voluntary movement, and is significantly stronger than the tremor of Parkinsonâ€™s disease. It usually involves the head, but not the legs. Facial expression and movements remain normal. Symptoms are symmetrical bilaterally. Rigidity, gait changes and postural instability do not occur. Essential tremor does not respond to levodopa.
- Alzheimerâ€™s disease may produce symptoms including gait changes, rigidity and slowed movements, but resting tremor will be absent.
- Huntingtonâ€™s chorea is a hereditary disorder characterized by dementia, rigidity, and slowed movements. The main differentiating symptom is chorea, as opposed to the tremor characteristic of Parkinsonâ€™s disease. Approximately one third of Huntingtonâ€™s patients respond to levodopa.
The mainstay of current Parkinsonâ€™s disease management is medication therapy. The first medication used for the treatment of Parkinsonâ€™s disease beginning in 1884 was apomorphine. In 1969, with a greater understanding of the disease process, levodopa was introduced. Although good symptom control was achieved, levodopa had a host of severe side effects. Addition of carbidopa provided better symptom control with fewer side effects. In recent years, the addition of a catechol-O-transferase (COMT) inhibitor has allowed reduced dosages of levodopa/carbidopa to be used, providing greater dopaminergic effect as well as longer duration of effectiveness.
Dopamine agonists, which mimic the action of dopamine, have also been introduced, and may be used in early Parkinsonâ€™s disease as monotherapy or, later, in combination with levodopa/carbidopa. Amantadine, which has only a limited effect on the symptoms of Parkinsonâ€™s disease, has been used to reduce the choreic movements that can be a side effect of dopaminergic therapy. Anticholinergics are no longer used for most patients, since they have a worse side effect profile and no greater effect than levodopa or the dopamine agonists.
Selegiline, released in the US in 1989, has caused some controversy because, although it has little effect on Parkinsonâ€™s disease symptoms, there are hints that it might slow the progression of the disease.
For more information, see Antiparkinson agents
Surgical treatment of Parkinsonâ€™s disease was first introduced in the 1950s, when thalamotomy was discovered to relieve tremor and rigidity, although it did not affect the slowed movements. Pallidotomy was found to improve tremor, rigidity and bradykinesia. In 1961, the introduction of levodopa greatly decreased the number of ablative procedures performed. Over time, it has become clear that long-term levodopa therapy becomes a balancing act between the symptoms of Parkinsonâ€™s disease and the side effects of the medication. For advanced Parkinsonâ€™s disease, surgery has once again become an option.
There are three sites within the brain that are targeted in the neurosurgical treatment of Parkinsonâ€™s disease: the globus pallidus interna, the subthalamic nucleus, and the ventralis intermedius nucleus of the thalamus. The current theory in surgical treatment is that the globus pallidus interna and the subthalamic nucleus are overactive. The two methods for decreasing this abnormal activity are ablation and deep brain stimulation.
Ablation is performed by introducing an electrode into the targeted area and heating it in order to produce a small necrotic area. This process is immediately effective, but irreversible. Deep brain stimulation involves the introduction of an implanted electrode into the target area. High-frequency stimulation of the area then temporarily creates the same effect as ablation, but is reversible. The electrode is controlled by a pulse generator implanted under the clavicle. The amplitude of the stimulation is adjustable, so it can be titrated to the response.
Generally, medication dosages can be reduced significantly after these procedures, but not eliminated.
A newer, controversial treatment is stem cell transplantation. The approaches that have been attempted include adrenal medullary grafts, pig xenografts, and embryonic dopamine neuron transplants. None of these have had a success rate approaching the standard surgical treatments. Younger Parkinsonâ€™s disease patients had slight improvement in their motor scores, but there was a small but significant population that developed intractable dyskinesias. All of these methods remain at the experimental stage. There is also ongoing research into methods of stimulating the stem cells that are present in every adultâ€™s brain to migrate to a damaged area, multiply and replace the damaged neurons.
Gene therapy is another experimental treatment aimed at stopping the loss of dopaminergic cells. This treatment would involve virally modifying the cells by replacing a defective gene or inserting a neuroprotective or neurorestorative protein.
A research model for Parkinsonâ€™s disease was discovered by accident in the 1980s when some people in California, while attempting to synthesize Demerol, accidentally synthesized MPTP. This compound induces Parkinsonâ€™s disease symptoms, and its discovery has allowed researchers to create animal models of Parkinsonâ€™s disease and advance their understanding of it.
An important aspect of the treatment of Parkinsonâ€™s disease is the use of nonpharmacological treatments. These include physical therapy, nutritional support, and patient and caregiver education. Acupuncture may provide some temporary relief from rigidity.
Eating foods high in antioxidants, such as blueberries, strawberries, prunes, kale and spinach, and taking antioxidant vitamin supplements such as vitamin C, vitamin E, selenium, and carotenes, may prevent oxidative problems. Dietary carbohydrate and protein composition as well as timing and frequency of meals have an influence on the effectiveness of levodopa. Levodopa should be taken with a high-carbohydrate meal, and protein consumption should be delayed to maximize the medicationâ€™s effect.
There are also foods which are natural sources of levodopa, such as the fava bean. 100 g of fava bean pods contain 250 mg of levodopa, the equivalent of one standard dose.
The nurseâ€™s role in the treatment of Parkinsonâ€™s disease is mainly that of an educator. There are several areas in which Parkinsonâ€™s disease patients can be expected to have problems, either from the disease process itself, or from the medications used to control their symptoms:
- Safety is an important issue for the patient with Parkinsonâ€™s disease. The motor difficulties accompanying the disease can set the patient up for falls, burns or other accidents. Falls are the sixth largest cause of death in the elderly population. Patients with Parkinsonâ€™s disease have a large number of additional risk factors, such as abnormal postural control mechanisms, orthostatic hypotension, cognitive decline, involuntary movements, and decreased range of motion. In addition, they have the risk factors associated with immobility, such as muscle weakness and decreased bone density. More than half of all Parkinsonâ€™s disease patients can be expected to have between one and five falls in a three-month period. The number of falls correlates with the duration of the disease and the severity of the symptoms. 80 percent of patients who experience episodes of freezing (inability to move oneâ€™s feet during ambulation) report falls. Walking difficulties, involuntary movements and postural problems are also closely linked to falling, as are postural hypotension, postural lean to one side, use of a cane or walker, requiring assistance with activities of daily living, having given up usual activities, and the daily use of alcohol. Living alone does not appear to increase the risk of falling, nor do use of stairs or type of residence. The peak time for falls appears to be two hours after medications and meals, possibly due to the increased activity at that time. Activities associated with falling are walking, turning, standing, and rising. Many patients may not be aware of the increased risk of falls. It is the nurseâ€™s responsibility to educate patients and caregivers about the risk of falls, and to make them aware of situations when falls are more likely. Use of alcohol should be discouraged, since it raises the risk of falling. Padding knees and elbows may help to prevent injuries while maintaining mobility despite deteriorating motor function.
Burns are also a safety risk for the Parkinsonâ€™s disease patient. Carrying hot liquids may present a challenge, due to tremor, involuntary movements and weakness. The nurse should educate patient and caregiver about methods of preventing scald injuries.
- Pain is a common, but often unidentified component of the Parkinsonâ€™s disease symptomatology. Limb rigidity may cause severe, radiating pain, as can rigidity of the face, chin, or jaw muscles. Dystonia, especially in the foot, but also in the face, arm, jaw, neck, or leg, may cause severe pain. Dystonia can occur before the first dose of medication in the morning, but it may occur as a peak-dose dyskinesia. Unilateral limb edema, proximal limb pain, and trigeminal neuralgia-like pain may also occur. Physical therapy, massage, and analgesics may decrease the pain, but generally adjustment of the antiparkinsonian therapy is more effective. Restless leg syndrome is characterized by unpleasant, sometimes painful, sensations in the legs, especially during periods of inactivity, which are relieved by movement or stimulation of the legs. Overnight subcutaneous apomorphine infusion can relieve the pain and reduce nocturnal leg spasms and awakenings. Abdominal pain, often due to the constipation associated with Parkinsonâ€™s disease, is also common. Primary pain in Parkinsonâ€™s disease is a general overall sensation of pain, paresthesia or tension that improves with motion and is more severe on the affected side. The cause of the pain is unknown. Many Parkinsonâ€™s disease patients also complain ofburning mouth pain or genital pain. Gabapentin or a dosage adjustment of levodopa may bring relief. Narcotics] are contraindicated in Parkinsonâ€™s disease due to the additional decrease in gastrointestinal motility which they cause.
- Gastrointestinal problems such as dysphagia, decreased gastric emptying, and constipation are common in Parkinsonâ€™s disease. Continuous assessment of bowel function is an important nursing function. A stool diary recording frequency, amount and consistency should be kept, and difficulty swallowing, abdominal distention and cramping, heartburn, indigestion, and early satiety should be assessed.
Dietary fiber, exercise, and fluids are the first line treatment for constipation. If these fail, stool softeners should be used, and lactulose may be added. Psyllium remains controversial due to the possibility of obstruction.
- Caregiver role strain is an area that needs to be addressed as well. The caregiver should have access to respite care and be told that it is all right to take a break and have some time for themselves. Counseling and community resource referrals should be initiated as needed.
Patients should be educated about their disease state and their treatments as well as all treatment options available. This should be done in several sessions to allow time for the patient to absorb the information. When the patient has the information available, they gain a sense of control, which is especially important in such a life-altering disease as Parkinsonâ€™s.